ARCH Venture Partners X, LLC
ARCH Venture Partners X, LLC's purchase track record
How the stock did after each of ARCH Venture Partners X, LLC's open-market purchases, measured from the purchase date. Several fills within a week count as one purchase.
| Purchase | Stock | Amount | 3 months | 6 months | S&P 500, 6 mo. |
|---|---|---|---|---|---|
| 10/27/2025 | NMRA | $5.00M | -24.2% | -17.5% | +4.3% |
| 8/1/2025 | PRME | $10.00M | +22.3% | -5.7% | +11.2% |
| 2/15/2024 | PRME | $20.00M | -9.7% | -43.7% | +10.2% |
| 9/19/2023 | NMRA | $51.00M | +21.4% | +17.1% | +16.5% |
| 10/24/2022 | PRME | $13.60M | +10.1% | -13.9% | +8.9% |
Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 25, 2026
Prime Medicine stock surges after FDA clears IND for PM647. Prime Medicine shares rose significantly after the U.S. FDA cleared the Investigational New Drug application for PM647, a gene editing therapy for alpha-1 antitrypsin deficiency. This regulatory approval allows the company to begin clinical trials for the treatment. The positive news for Prime Medicine occurred alongside a broader decline in gene-editing stocks triggered by recent developments involving Anthropic AI.
Transaction History
| NMRA | ▲ Buy | Open Market | 1,915,700 | $5.0M | 10/27/2025 | View on chart |
| PRME | ▲ Buy | Open Market | 3,030,300 | $10.0M | 8/1/2025 | View on chart |
| PRME | ▲ Buy | Open Market | 3,200,000 | $20.0M | 2/15/2024 | View on chart |
| NMRA | ▼ Sell | Other | 1,176,593 | — | 12/8/2023 | View on chart |
| NMRA | ▼ Sell | Other | 703,061 | — | 12/8/2023 | View on chart |
| NMRA | ▼ Sell | Other | 2,124,143 | — | 9/19/2023 | View on chart |
| NMRA | ▲ Buy | Open Market | 1,500,000 | $25.5M | 9/19/2023 | View on chart |
| NMRA | ▼ Sell | Other | 1,144,973 | — | 9/19/2023 | View on chart |
| NMRA | ▼ Sell | Other | 6,576,400 | — | 9/19/2023 | View on chart |
| NMRA | ▼ Sell | Other | 6,895,021 | — | 9/19/2023 | View on chart |
| NMRA | ▼ Sell | Other | 684,167 | — | 9/19/2023 | View on chart |
| NMRA | ▼ Sell | Other | 1,144,973 | — | 9/19/2023 | View on chart |
| NMRA | ▼ Sell | Other | 6,895,021 | — | 9/19/2023 | View on chart |
| NMRA | ▼ Sell | Other | 6,576,400 | — | 9/19/2023 | View on chart |
| NMRA | ▼ Sell | Other | 2,124,143 | — | 9/19/2023 | View on chart |
| NMRA | ▲ Buy | Open Market | 1,500,000 | $25.5M | 9/19/2023 | View on chart |
| NMRA | ▼ Sell | Other | 684,167 | — | 9/19/2023 | View on chart |
| PRME | ▼ Sell | Other | 5,728,297 | — | 10/24/2022 | View on chart |
| PRME | ▲ Buy | Open Market | 400,000 | $6.8M | 10/24/2022 | View on chart |
| PRME | ▲ Buy | Open Market | 400,000 | $6.8M | 10/24/2022 | View on chart |
| PRME | ▼ Sell | Other | 5,728,297 | — | 10/24/2022 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 15, 2026
NMRA noted among top stock movers today
NMRA appeared in today's list of top stock movements, reflecting notable price activity. The stock is currently trading near its support level of $1.60 and shows a low RSI, suggesting oversold conditions. Analyst consensus target remains at $6.14, well above the current price range.
NMRA noted among top stock movers today. NMRA appeared in today's list of top stock movements, reflecting notable price activity. The stock is currently trading near its support level of $1.60 and shows a low RSI, suggesting oversold conditions. Analyst consensus target remains at $6.14, well above the current price range.